0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PD-1

PD-1

Brief Information

Name:Programmed cell death protein 1
Target Synonym:Programmed cell death protein 1,CD279,hPD-1,PDCD1,Programmed Cell Death 1,Systemic Lupus Erythematosus Susceptibility 2,Protein PD-1,PD1,Programmed Cell Death 1 Protein,CD279 Antigen,HPD-L,HSLE1,SLEB2,PD-1,Programmed Cell Death 1 Receptor
Number of Launched Drugs:8
Number of Drugs in Clinical Trials:73
Lastest Research Phase:Approved

Licensing

Project item Indications Research phase Cooperation demands
BBS21008 Solid tumors such as lung cancer, gastric carcinoma, esophagus cancer, cervical cancer. Pre-clinical, CMC developing; Project transfer or co-development. (the project’s company is in the startup stage and seek external cooperation to accelate drug research and development.)

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
PD1-H52H2 Human Human PD-1 Protein, His tag (Nanoparticle)
PD1-H52H2-structure
PD1-H52H2-sds
PD1-H52H2-elisa_1
PD1-C52H9 Canine Canine PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-C52H9-structure
PD1-C52H9-sds
PD1-H82A4 Human Biotinylated Human PD-1 / PDCD1 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
PD1-H82A4-structure
PD1-H82A4-sds
PD1-H82A4-elisa_1
PD1-R52H3 Rhesus macaque Rhesus macaque PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-R52H3-structure
PD1-R52H3-sds
PD1-R52H3-elisa_1
PD1-H52H6 Human Human PD-1 / PDCD1 Full Length Protein, His Tag
PD1-H52H6-structure
PD1-H52H6-sds
PD1-H52H6-elisa_1
PD1-H82F4 Human Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™,His Tag (MALS verified)
PD1-H82F4-structure
PD1-H82F4-sds
PD1-H82F4-hplc
PD1-H82F4-elisa_1
PD1-C82E6 Cynomolgus Biotinylated Cynomolgus PD-1 / PDCD1 Protein, His,Avitag™
PD1-C82E6-structure
PD1-C82E6-sds
PD1-C82E6-elisa_1
PD1-HP2F2 Human PE-Labeled Human PD-1 / PDCD1 Protein, Fc,His Tag (recommended for neutralizing assay)
PD1-HP2F2-structure
PD1-H5255 Human Human PD-1 / PDCD1 Protein, Mouse IgG2a Fc Tag (HPLC-verified)
PD1-H5255-structure
PD1-H5255-sds
PD1-H5255-hplc
PD1-H5255-elisa_1
PD1-H522a Human Human PD-1 / PDCD1 Protein, His Tag, low endotoxin (MALS verified)
PD1-H522a-structure
PD1-H522a-sds
PD1-H522a-hplc
PD1-H522a-elisa_1
EPC-V1 Monkey ELISA Assay Kit for Anti-PD-1 h-mAb in Monkey Serum
EPC-V1-elisa_1
EPM-V1 Mouse ELISA Assay Kit for Anti-PD-1 h-mAb in Mouse Serum
EPM-V1-elisa_1
PD1-H5259 Human Human PD-1 / PDCD1 Protein, Llama IgG2b Fc Tag, low endotoxin
PD1-H5259-structure
PD1-H5259-sds
PD1-H5259-elisa_1
EPH-V1 Human ELISA Assay Kit for Anti-PD-1 h-mAb in Human Serum
EPH-V1-elisa_1
PD1-H82F1 Human Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™ (MALS verified)
PD1-H82F1-structure
PD1-H82F1-sds
PD1-H82F1-elisa_1
PD1-RB5251 Rabbit Rabbit PD-1 / PDCD1 Protein, Fc Tag
PD1-RB5251-structure
PD1-RB5251-sds
PD1-RB5251-elisa_1
PD1-M52A4 Mouse Mouse PD-1 / PDCD1 Protein, Mouse IgG2a Fc Tag
PD1-M52A4-structure
PD1-M52A4-sds
PD1-M52A4-elisa_1
PD1-R52H2 Rat Rat PD-1 / PDCD1 Protein, His Tag
PD1-R52H2-structure
PD1-R52H2-sds
PD1-R52H2-elisa_1
PD1-H82E4 Human Biotinylated Human PD-1 / PDCD1 Protein, Avitag™,His Tag (recommended for biopanning) (MALS verified)
PD1-H82E4-structure
PD1-H82E4-sds
PD1-H82E4-elisa_1
PD1-R52H0 Rabbit Rabbit PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-R52H0-structure
PD1-R52H0-sds
PD1-M82F4 Mouse Biotinylated Mouse PD-1 / PDCD1 Protein, Fc,Avitag™
PD1-M82F4-structure
PD1-M82F4-sds
PD1-M82F4-elisa_1
PD1-R5253 Rat Rat PD-1 / PDCD1 Protein, Fc Tag
PD1-R5253-structure
PD1-R5253-sds
PD1-R5253-elisa_1
PD1-M5259 Mouse Mouse PD-1 / PDCD1 Protein, Fc Tag
PD1-M5259-structure
PD1-M5259-sds
PD1-M5259-elisa_1
PD1-M5259-elisa_2
PD1-H5284 Human Human PD-1 / PDCD1 Protein, Strep Tag
PD1-H5284-structure
PD1-H5284-sds
PD1-H5284-elisa_1
PD1-M5228 Mouse Mouse PD-1 / PDCD1 Protein, His Tag
PD1-M5228-structure
PD1-M5228-sds
PD1-C5254 Cynomolgus Cynomolgus PD-1 / PDCD1 Protein, Fc Tag
PD1-C5254-structure
PD1-C5254-sds
PD1-C5254-elisa_1
PD1-C5223 Cynomolgus Cynomolgus PD-1 / PDCD1 Protein, His Tag
PD1-C5223-structure
PD1-C5223-sds
PD1-C5223-elisa_1
PD1-C5223-elisa_2
PD1-H5257 Human Human PD-1 / PDCD1 Protein, Fc Tag, low endotoxin (MALS Verified)
PD1-H5257-structure
PD1-H5257-sds
PD1-H5257-hplc
PD1-H5257-elisa_1
PD1-H5257-elisa_2
PD1-H5221 Human Human PD-1 / PDCD1 Protein, His Tag (MALS Verified)
PD1-H5221-structure
PD1-H5221-sds
PD1-H5221-hplc
PD1-H5221-elisa_1
PD1-H5221-elisa_2

Part of Bioactivity data

PD1-HP2F2-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that PE-Labeled Human PD-1, Fc,His Tag (Cat. No. PD1-HP2F2) can bind to 293T cells overexpressing human PD-L1. 1 μL stock solution per million cells (QC tested).

PD1-HP2F2-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of PE-Labeled Human PD-1, Fc,His Tag (Cat. No. PD1-HP2F2) to 293T overexpressing PD-L1 was inhibited by increasing concentration of neutralizing anti-human PD-L1 antibody. The IC50 is 0.29 μg/mL (QC tested).

PD1-M5259-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) on Protein A Chip can bind Mouse PD-L1, His Tag (Cat. No. PD1-M5220) with an affinity constant of 2.16 μM as determined in SPR assay (Biacore T200) (Routinely tested).

PD1-M5259-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Mouse PD-L1, His Tag (Cat. No. PD1-M5220) on CM5 Chip via Anti-His antibody can bind Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) with an affinity constant of 1.37 μM as determined in SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

PDCD1,PD1,CD279,SLEB2

Background

How a therapeutic antibody is metabolized in the body is pertinently relevant to its efficacy. Therefore, pharmacokinetics study is an important part of the drug development. PD-1 is probably the most targeted molecule in today’s pharmaceutical industry, thanking to the clinical success of Keytruda® and Opdivo®. Many investigational anti-PD-1 mAbs are being developed. There is a growing need for a standard assay that can be used to facilitate the study of their pharmacokinetics.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Prolgolimab BCD-100 Approved Biocad Forteca Russian Federation Melanoma Biocad 2020-04-01 Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms Details
Cemiplimab REGN-2810; SAR-439684 Approved Regeneron Pharmaceuticals Inc Libtayo EU Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung Regeneron Ireland Uc 2018-09-28 Diffuse Intrinsic Pontine Glioma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Glioma; Lymphoma; Carcinoma, Squamous Cell; Peritoneal Neoplasms; Ovarian Neoplasms; Hepatitis B; Prostatic Neoplasms; Central Nervous System Neoplasms; Skin Neoplasms; Hodgkin Disease; Glioblastoma; Carcinoma, Renal Cell; Carcinoma, Basal Cell; Squamous Cell Carcinoma of Head and Neck; Solid tumours Details
Camrelizumab SHR-1210; INCSHR-1210; HR-301210 Approved Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd 艾立妥, 艾瑞卡 Mainland China Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Suzhou Suncadia Biopharmaceuticals Co Ltd 2019-05-29 Respiratory Tract Neoplasms; Melanoma; Uterine Cervical Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Genital Neoplasms, Female; Urologic Neoplasms; Lymphoma, Extranodal NK-T-Cell; Solid tumours; Nasopharyngeal Carcinoma; Breast Neoplasms; Lung Diseases; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Hodgkin Disease; Carcinoma, Renal Cell; Stomach Neoplasms; Bronchial Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms; Carcinoma, Bronchogenic Details
Toripalimab TAB-001; JS-001; SO-001 Approved Suzhou Union Biopharm Biosciences Co Ltd, Shanghai Junshi Biosciences Co Ltd 拓益 Mainland China Carcinoma, Transitional Cell Shanghai Junshi Biological Engineering Co Ltd 2018-12-17 Urinary Bladder Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Lymphoma; Esophageal Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Liposarcoma; Neuroendocrine Tumors; Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Kidney Neoplasms Details
Sintilimab IBI-308 Approved Innovent Biologics(Suzhou) Co Ltd Tyvyt, 达伯舒 Mainland China Carcinoma, Hepatocellular Innovent Biologics(Suzhou) Co Ltd 2018-12-24 Lymphoma, Extranodal NK-T-Cell; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Nasopharyngeal Carcinoma; Osteosarcoma; Adenocarcinoma of Lung; Hodgkin Disease; Pancreatic Neoplasms; Esophageal Neoplasms; Solid tumours Details
Dostarlimab WBP-285; TSR-042; ANB-011 Approved Anaptysbio JEMPERLI United States Solid tumours null 2021-04-21 Solid tumours; Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Pembrolizumab SCH-900475; h409A11; MK-3475 Approved Merck & Co Inc 可瑞达, Keytruda EU Esophageal Neoplasms Merck Sharp & Dohme Bv 2014-09-04 Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Ovarian Neoplasms; Kidney Neoplasms; Endocrine Gland Neoplasms; Lymphoma, B-Cell; Liver Neoplasms; Skin Melanoma; Leiomyosarcoma; Hematologic Neoplasms; Carcinoma; Anus Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thoracic Neoplasms; Bronchial Neoplasms; Carcinoma, Merkel Cell; Viremia; Carcinoid Tumor; Rectal Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Neuroectodermal Tumors; Glioblastoma; Inflammatory Breast Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Thyroid Carcinoma, Anaplastic; Neoplasms, Glandular and Epithelial; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Neoplasms, Squamous Cell; Skin Neoplasms; Nasopharyngeal Neoplasms; Adenocarcinoma of Lung; Salivary Gland Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Microsatellite instability-high cancer; Urologic Diseas Details
Penpulimab AK-105 Approved Zhongshan Akeso Biopharma Co Ltd 安尼可 Mainland China Hodgkin Disease Zhengda Tianqing Kangfang (Shanghai) Biomedical Technology Co Ltd 2021-08-03 Solid tumours; Hodgkin Disease; Neoplasms; Nasopharyngeal Carcinoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Nivolumab ONO-4538; ono-0123; BMS-936558; MDX-1106; BMS-936558-01 Approved Bristol-Myers Squibb Company, Ono Pharmaceutical Co Ltd 欧狄沃, Opdivo EU Esophageal Neoplasms Bristol-Myers Squibb Pharma Eeig 2014-07-04 Diarrhea; Lung Neoplasms; Peritoneal Neoplasms; Ureteral Neoplasms; Genital Neoplasms, Female; Hepatitis C; Colorectal Neoplasms; Sarcoma, Ewing; Brain Neoplasms; Hepatitis B; Esophageal Squamous Cell Carcinoma; Lymphoma, Mantle-Cell; Neuroblastoma; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Microsatellite Instability; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Esophageal adenocarcinoma; Large intestine neoplasm; Thyroid Cancer, Papillary; Uterine Cervical Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Multiple Myeloma; Urogenital Neoplasms; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Glioma; Lymphoma; Carcinoma, Squamous Cell; Chondrosarcoma; Irritable Bowel Syndrome; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Skin Melanoma; Liver Neoplasms; Leukemia; Carcinoma, Merkel Cell; Ependymoma; Solid tumours; Medullobl Details
Tislelizumab BGB-A317 Approved Beigene Ltd 百泽安 Mainland China Carcinoma, Hepatocellular Beigene (Shanghai) Biotechnology Co Ltd 2019-12-26 Lymphoma, Mantle-Cell; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lymphoma, T-Cell; Lymphoma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Lymphoma, T-Cell, Cutaneous; Lymphoma, Large-Cell, Anaplastic; Nasopharyngeal Carcinoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell, Peripheral; Lymphoma, Follicular; Breast Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell, Marginal Zone; Solid tumours Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SL-279252 TAK-252; SL-279252 Phase 1 Clinical Shattuck Labs Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Hodgkin Disease; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
INSIX RA (Indus Biotech) Clinical Indus Biotech Pvt Ltd Arthritis, Rheumatoid; Inflammation Details
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) ICTCAR-014 Phase 2 Clinical Innovative Cellular Therapeutics Co Ltd Lymphoma, Non-Hodgkin Details
PD-1 knockout engineered T cells (Chengdu MedGenCell) Phase 2 Clinical West China Hospital Of Sichuan University, Chengdu Medgencell Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell Details
PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) Phase 2 Clinical Anhui Kedgene Biotechnology, Hangzhou Cancer Hospital Esophageal Neoplasms Details
W0180 Phase 1 Clinical Pierre Fabre Medicament Neoplasms Details
Programmed cell death 1 antibody (Sun Yat-sen University) Phase 2 Clinical Sun Yat-Sen University Carcinoma, Hepatocellular Details
PD-1 knockout EBV-CTL (Nanjing Medical University) Phase 2 Clinical Nanjing Medical University Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma Details
EBV-Specific TCR-T Cell therapy (Xinqiao Hospital of Chongqing) Phase 2 Clinical Chongqing Xinqiao Hospital Squamous Cell Carcinoma of Head and Neck Details
IBI315 IBI315; IBI-315 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd, Hanmi Pharmaceutical Co Ltd Neoplasms Details
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) Phase 2 Clinical Shanghai Cell Therapy Research Institute Neoplasms Details
ONO-4685 ONO-4685 Phase 1 Clinical Merus Autoimmune Diseases Details
YBL-006 YBL-006; YBL 006 Phase 1 Clinical Solid tumours; Neoplasms Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Multiple Myeloma Details
BCD-217 BCD-217 Phase 2 Clinical Biocad Melanoma Details
PD-1 knockout engineered T cells (Cell Biotech) Phase 1 Clinical Cell Biotech Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Prostatic Neoplasms Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) Phase 1 Clinical Shanxiweiqidaguangming Pharmaceutical Co Ltd Solid tumours Details
MiHA-loaded PD-L silenced DC vaccination (Radboud University) Phase 2 Clinical Radboud University Nijmegen Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
GNR-051 GNR-051 Phase 1 Clinical Generium Pharmaceuticals Carcinoma, Renal Cell; Melanoma; Carcinoma, Non-Small-Cell Lung Details
CA-170 CA-170; AUPM-170 Phase 2 Clinical Aurigene Solid tumours; Neoplasms Details
Pidilizumab CT-011; MDV-9300 Phase 2 Clinical Curetech Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Multiple Myeloma; Lymphoma, Follicular; Prostatic Neoplasms; Hepatitis C; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Glioma; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Hepatocellular; Hepatitis C, Chronic Details
9MW1111 9MW1111 Phase 1 Clinical Mabwell (Shanghai) Bioscience Co Ltd Solid tumours Details
IMU-201 IMU-201 Phase 1 Clinical Imugene Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
MEDI-0680 AMP-514; MEDI-0680 Phase 2 Clinical Medimmune Kidney Neoplasms; Lymphoma, B-Cell; Carcinoma, Renal Cell Details
MEDI-5752 MEDI-5752 Phase 1 Clinical Medimmune Llc Solid tumours; Carcinoma, Renal Cell; Neoplasms Details
STW204单抗 STW-204 Phase 1 Clinical Suzhou Stainwei Biotech Inc Solid tumours Details
CMAB-819 CMAB8-19 Phase 1 Clinical Sinomab Bioscience Ltd Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
CS-1003 CS-1003 Phase 3 Clinical Cstone Pharmaceuticals Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular Details
IBI318 IBI-318; LY-3434172; LY3434172 Phase 2 Clinical Eli Lilly And Company, Innovent Biologics(Suzhou) Co Ltd Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
RB-0004 RB-0004 Phase 1 Clinical Reyoung Pharmaceutical Co Ltd Solid tumours; Lymphoma Details
Recombinant humanized anti-PD-1 monoclonal antibody (Sinocelltech) SCT-I10A Phase 3 Clinical Shenzhou Cell Engineering Co Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Lymphoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular Details
ONCR-177 ONCR-177 Phase 1 Clinical Oncorus Liver Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma Details
Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) Phase 2 Clinical Anhui Anke Biotechnology (Group) Co Ltd Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lung Neoplasms Details
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) Phase 1 Clinical Beijing Mali Biotechnology Co Ltd, Chengdu Yinhe Biomedicine Co Ltd Lymphoma, B-Cell Details
Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) Phase 1 Clinical Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd Solid tumours; Stomach Neoplasms Details
Recombinant human PD-1 antibody herpes simplex virus Phase 1 Clinical Yangshengtang Co Ltd, Xiamen University Head and Neck Neoplasms; Liver Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Melanoma; Uterine Cervical Neoplasms Details
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) Phase 1 Clinical Lymphoma, B-Cell Details
Recombinant humanized anti-PD-1 monoclonal antibody (Bio-Thera) BAT-1306 Phase 2 Clinical Bio-Thera Solutions Ltd Solid tumours; Liver Neoplasms; Stomach Neoplasms; Colorectal Neoplasms Details
MGD-019 (MacroGenics) MGD-019 Phase 1 Clinical Macrogenics Solid tumours; Skin Melanoma; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Nivolumab Biosimilar LY-01015 Phase 1 Clinical Luye Pharma Group Ltd Neoplasms Details
JTX-4014 (Jounce Therapeutics) JTX-4014 Phase 2 Clinical Jounce Therapeutics Neoplasms; Carcinoma, Non-Small-Cell Lung Details
XmAb-23104 (Xencor) Phase 1 Clinical Xencor Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Sarcoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
CC-90006 C-90006; CC-90006 Phase 1 Clinical Anaptysbio Autoimmune Diseases; Psoriasis Details
Sym-021 Sym-021 Phase 1 Clinical Symphogen Solid tumours; Lymphoma; Neoplasm Metastasis Details
609-A (SBio) 609-A Phase 1 Clinical Shenyang Sunshine Pharmaceutical Co Ltd Solid tumours Details
Sasanlimab RN-888; PF-6801591; PF-06801591 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Squamous Cell; Endometrial Neoplasms; Bile Duct Neoplasms; Prostatic Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Solid tumours; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms Details
Nivolumab/Relatlimab BMS-986213; BMS-936558/BMS-986016 Phase 3 Clinical Bristol-Myers Squibb Company Esophageal Neoplasms; Stomach Neoplasms; Melanoma Details
MAX-10181 MAX-10181; MAX-1 Phase 1 Clinical Guangzhou Maxinovel Pharmaceiticals Co Ltd Solid tumours Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shandong Xinshidai Pharmaceutical) Phase 2 Clinical Shandong New Time Pharmaceutical Co Ltd Lymphoma, T-Cell, Peripheral; Solid tumours; Carcinoma, Transitional Cell; Neurolymphomatosis; Lymphoma; Uterine Cervical Neoplasms Details
Spartalizumab PDR-001 Phase 3 Clinical Novartis Pharma Ag Sarcoma, Alveolar Soft Part; Neuroendocrine Tumors; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Nasopharyngeal Carcinoma; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Bone Marrow Diseases; Primary Myelofibrosis; Lung Neoplasms; Carcinoma, Pancreatic Ductal; Chordoma; Endometrial Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Esophageal adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Persistent Fetal Circulation Syndrome; Adenocarcinoma; Stomach Neoplasms; Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Leukemia; Leukemia, Myeloid; Kidney Neoplasms; Preleukemia; Hematologic Diseases; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Leukemia, Myelomonocytic, Chronic; Neoplasms, Squamous Cell; Pancreatic Neoplasms; Thyroid Carcinoma, Anaplastic; Small Cell Lung Carcinoma; Myelodysp Details
Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) Details
SSGJ-705 SSGJ-705 Phase 1 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Solid tumours Details
HX-009 HX-009 Phase 2 Clinical Hangzhou Hansi Biomedicine Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd Solid tumours; Liver Neoplasms; Hematologic Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung; Melanoma Details
MW-11 MW-11 Phase 1 Clinical Mabwell (Shanghai) Bioscience Co Ltd Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Nasopharyngeal Neoplasms; Hodgkin Disease; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma Details
SSI-361 LVGN-3616; SSI-361 Phase 2 Clinical Lyvgen Biopharma(HK)Ltd Neoplasms Details
Ezabenlimab BI-754091 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Head and Neck Neoplasms; Solid tumours; Rectal Neoplasms; Colonic Neoplasms; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms Details
SI-B003 SI-B003 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
T3011疱疹病毒(深圳市亦诺微医药) Phase 2 Clinical Shenzhen Yinuowei Pharmaceutical Technology Co Ltd Head and Neck Neoplasms; Solid tumours; Esophageal Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Tebotelimab PD-1 X LAG-3; MGD-013 Phase 3 Clinical Macrogenics Small Cell Lung Carcinoma; Carcinoma, Hepatocellular; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma; Endometrial Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms; Solid tumours; Hematologic Neoplasms Details
LZM-009 LZM-009 Phase 2 Clinical Livzon(Group) Pharmaceutical Factory Solid tumours; Thymoma; Carcinoma, Non-Small-Cell Lung Details
IBI319 IBI-319 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Neoplasms Details
Recombinant human anti-PD-1 monoclonal antibody(Yiyi Health Technology) Phase 1 Clinical Shanghai Yunyi Health Technology Development Co Ltd Neoplasms Details
MK-4280A MK-4280A Phase 1 Clinical Moshadong R & D (China) Co Ltd, Msd Ireland (Carlow) Merck Sharp & Dohme Corp Solid tumours Details
IBI-321 IBI-321 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
HLX-10 HLX-10 Phase 3 Clinical Shanghai Henlius Biotech Co Ltd Small Cell Lung Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Colorectal Neoplasms; Microsatellite Instability; Triple Negative Breast Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Hepatitis B, Chronic; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Head and Neck Neoplasms; Liver Neoplasms Details
Recombinant human anti-PD-1 monoclonal antibody(Sumgen) SG-001 Phase 2 Clinical Hangzhou Sumgen Biotechnology Co Ltd Solid tumours; Carcinoma, Ovarian Epithelial; Mesothelioma; Peritoneal Neoplasms; Lymphoma; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
JS201 JS201 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Neoplasms Details
AZD-7789 AZD-7789 Phase 2 Clinical AstraZeneca Ag Carcinoma, Non-Small-Cell Lung Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) Phase 1 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Solid tumours Details
AK-112 AK-112 Phase 2 Clinical Zhongshan Akeso Biopharma Co Ltd Ovarian Neoplasms; Solid tumours; Neoplasms; Small Cell Lung Carcinoma; Genital Neoplasms, Female; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis Details
EMB-02 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours Details
INCB-086550 INCB-086550 Phase 2 Clinical Incyte Corp Solid tumours; Carcinoma, Renal Cell; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Cetrelimab JNJ-3283; JNJ-63723283 Phase 3 Clinical Johnson & Johnson Carcinoma, Transitional Cell; Neoplasms; Multiple Myeloma; Urinary Bladder Neoplasms Details
RO-7247669 RO-7247669 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
RO-7121661 RG-7769; RO-7121661 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
QL-1706 QL-1706; PSB-205 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Solid tumours; Liver Neoplasms; Neoplasms Details
TY-101 TY-101; TY101 Phase 2 Clinical Tayu Huaxia Biotech Medical Group Co Ltd Solid tumours; Lymphoma Details
XmAb20717 XmAb-20717 Phase 2 Clinical Xencor Breast Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Neuroendocrine; Thymoma; Colorectal Neoplasms; Astrocytoma; Prostatic Neoplasms; Vulvar Neoplasms; Solid tumours; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Adnexal Diseases; Mesothelioma; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Carcinoma, Renal Cell Details
Budigalimab ABBV-181 Phase 2 Clinical Abbvie Inc Ovarian Neoplasms; Solid tumours; Head and Neck Neoplasms; HIV Infections; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
AK-104 AK-104 Phase 3 Clinical Zhongshan Akeso Biopharma Co Ltd Lymphoma, T-Cell, Peripheral; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Microsatellite instability-high cancer; Nasopharyngeal Carcinoma; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Retifanlimab INCMGA-0012; INCMGA-00012; MGA-012 Phase 3 Clinical Macrogenics Carcinoma, Transitional Cell; Carcinoma, Endometrioid; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Endometrial Neoplasms; Carcinoma, Squamous Cell; Prostatic Neoplasms; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms Details
AMG-404 AMG-404 Phase 1 Clinical Amgen Inc Solid tumours; Small Cell Lung Carcinoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms Details
AZD-2936 AZD-2936 Phase 2 Clinical Astrazeneca Plc Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop